News
-
-
-
PRESS RELEASE
Vallourec Second Quarter 2025 Results
-
-
-
-
-
PRESS RELEASE
BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
BB Biotech AG outperforms Nasdaq Biotech Index in Q2 2025, with strong USD returns but currency drag in CHF. Strategic acquisitions and advancements in portfolio companies drive innovation and value creation -
-
PRESS RELEASE
FORVIA HELLA presents half-year results for 2025: Sales at previous year's level, largely stable earnings development; outlook is confirmed
FORVIA HELLA presents 2025 half-year results: sales stable, earnings improve; outlook confirmed. Group sales €4.0 billion, operating income margin 6.0 percent